Results 1 to 10 of about 327,203 (311)

Living with systemic lupus erythematosus in 2020: a European patient survey

Lupus Science and Medicine, 2021
Objective The aim of this study was to analyse the 2020 burden of Systemic Lupus Erythematosus (SLE) in Europe, from the patients’ perspective.Methods In May 2020, Lupus Europe, the European umbrella patient association for SLE, designed and disseminated
Alain Cornet, Kirsi Myllys, Jeanette Andersen, Angela Edwards   +3 more
doaj   +1 more source

Membrane and Soluble CD137 in Systemic Lupus Erythematosus: Role as Biomarkers for Disease Activity

Journal of Immunology Research, 2023
Objective. The role of T cells in the pathogenesis of systemic lupus erythematosus (SLE) has recently gained attention. Costimulatory molecules are membrane proteins strictly associated with T-cell receptor (TCR), acting by activating or inhibiting T ...
Fulvia Ceccarelli, Francesco Natalucci, Alessandra Di Filippo, Giulio Olivieri, Chiara Napoletano, Aurelia Rughetti, Marianna Nuti, Ilaria Grazia Zizzari, Fabrizio Conti   +8 more
doaj   +1 more source

Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence

Lupus Science and Medicine, 2021
Background Use of hydroxychloroquine (HCQ) is common in patients with lupus erythematosus. Long-term use (ie, ≥5 years) and high-dose HCQ (ie, >5 mg/kg/day) are both risk factors for developing HCQ retinopathy.
Ronald F van Vollenhoven, Alain Cornet, Jeanette Andersen, Zgjim Osmani, Thijs J Schrama, Wendy Zacouris-Verweij, Susan Frankel, Irene E M Bultink   +7 more
doaj   +1 more source

Patients with systemic lupus erythematosus and their experience with vaccination against COVID-19: a descriptive and explanatory study

Reumatismo, 2022
Not ...
F. Ceccarelli, V. Covelli, G. Olivieri, F. Natalucci, C. Alessandri, F. Conti   +5 more
doaj   +1 more source

Development of Systemic Autoimmune Diseases in Healthy Subjects Persistently Positive for Antiphospholipid Antibodies: Long-Term Follow-Up Study

Biomolecules, 2022
We longitudinally followed a single-center cohort of anti-phospholipid (aPL) positive healthy subjects to evaluate the evolution to systemic autoimmune diseases (sAD) and to describe clinical and serological associated features.
Fulvia Ceccarelli, Francesco Natalucci, Giulio Olivieri, Carmelo Pirone, Licia Picciariello, Valeria Orefice, Simona Truglia, Francesca Romana Spinelli, Cristiano Alessandri, Antonio Chistolini, Fabrizio Conti   +10 more
doaj   +1 more source

Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis

RMD Open, 2019
Introduction Eosinophilic granulomatosis with polyangiitis (EGPA) is a subset of antineutrophil cytoplasmic antibodies (ANCA) associated vasculitis with distinct pathophysiological mechanisms, clinical features and treatment responses.
David Jayne, Rachel B Jones, Vítor Teixeira, Aladdin J Mohammad, Rona Smith   +4 more
doaj   +1 more source

Anti-carbamylated protein antibodies as a new biomarker of erosive joint damage in systemic lupus erythematosus

Arthritis Research & Therapy, 2018
Background The application of more sensitive imaging techniques, such as ultrasonography (US), changed the concept of non-erosive arthritis in systemic lupus erythematosus (SLE), underlining the need for biomarkers to identify patients developing the ...
Fulvia Ceccarelli, Carlo Perricone, Tania Colasanti, Laura Massaro, Enrica Cipriano, Monica Pendolino, Francesco Natalucci, Riccardo Mancini, Francesca Romana Spinelli, Guido Valesini, Fabrizio Conti, Cristiano Alessandri   +11 more
doaj   +1 more source

Hydroxychloroquine availability during COVID-19 crisis and its effect on patient anxiety

Lupus Science and Medicine, 2021
Objective To report the results of a survey exploring the experience of patients with SLE facing hydroxychloroquine (HCQ) shortage that occurred during the early phases of the COVID-19 pandemic.Methods A survey was designed by Lupus Europe’s patient ...
Alain Cornet, Chiara Tani, Marta Mosca, Jeanette Andersen   +3 more
doaj   +1 more source

Gradual Glucocorticosteroid Withdrawal Is Safe in Clinically Quiescent Systemic Lupus Erythematosus

ACR Open Rheumatology, 2021
Objectives Patients with systemic lupus erythematosus (SLE) are usually treated with glucocorticosteroids even during periods of clinically quiescent disease.
Konstantinos Tselios, Dafna D. Gladman, Jiandong Su, Murray B. Urowitz   +3 more
doaj   +1 more source

Joint involvement in patients affected by systemic lupus erythematosus: application of the swollen to tender joint count ratio

Reumatismo, 2015
Joint involvement is a common manifestation in systemic lupus erythematosus (SLE). According to the SLE disease activity index 2000 (SLEDAI-2K), joint involvement is present in case of ≥2 joints with pain and signs of inflammation.
E. Cipriano, F. Ceccarelli, L. Massaro, F. R. Spinelli, C. Alessandri, C. Perricone, G. Valesini, F. Conti   +7 more
doaj   +1 more source